SARS-CoV-2 infection can cause severe respiratory COVID-19. However, many individuals
present with isolated upper respiratory symptoms, suggesting potential to constrain viral …

Coordinated local mucosal and systemic immune responses following severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection either protect against …

The nasal epithelium is a plausible entry point for SARS-CoV-2, a site of pathogenesis and
transmission, and may initiate the host response to SARS-CoV-2. Antiviral interferon (IFN) …

The nasal mucosa constitutes the primary entry site for respiratory viruses, including severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While the imbalanced innate …

Abstract SARS-CoV-2, the causative agent of COVID-19, has tragically burdened individuals
and institutions around the world. There are currently no approved drugs or vaccines for the …

To investigate the immune response and mechanisms associated with severe coronavirus
disease 2019 (COVID-19), we performed single-cell RNA sequencing on nasopharyngeal …

Abstract Coronavirus disease 2019 (COVID-19) outcomes vary from asymptomatic infection
to death. This disparity may reflect different airway levels of the SARS-CoV-2 receptor …

There are currently limited Food and Drug Administration (FDA)-approved drugs and
vaccines for the treatment or prevention of Coronavirus Disease 2019 (COVID-19) …

The outbreaks of 2019 novel coronavirus disease (COVID-19) caused by SARS-CoV-2
infection have posed a severe threat to global public health. It is unclear how the human …

Research conducted on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pathogenesis and coronavirus disease 2019 (COVID-19) generally focuses on the systemic …